We engineer synthetic mRNA, siRNA, ASO, and guide RNAs to improve their stability, therapeutic efficiency, and immunogenicity profiles. Our goal is to develop therapeutic RNA structures optimized for applications in vaccines, gene modulation, and genome editing, with a focus on targeting cancer and rare genetic diseases. . 

We design and synthesize lipid- and polymer-based nanoparticles capable of cell- or tissue-specific delivery of RNA payloads. By incorporating cleavable peptides, ligands, or nanobodies, we achieve precise delivery to various target tissues. 

We develop CRISPR-based RNA delivery systems for transient and precise genome modulation in immune and tumor cells. By integrating guide RNA engineering and cell-targeted nanoparticle formulations, our platform enables selective editing of immune checkpoints, tumor-associated antigens, and regulatory pathways. These technologies are being applied to enhance cancer immunotherapy, including CAR-X engineering and next-generation mRNA-based cancer vaccines.